ASH: ZymoGenetics presents TACI-ig data

ZymoGenetics, Inc. (Nasdaq: ZGEN - News) announced that preliminary data were presented from a Phase 1 study of TACI-Ig in patients with multiple myeloma and Waldenstrom's macroglobulinemia. Based on nine patients enrolled to date, study authors observed that treatment with TACI-Ig reduced circulating polyclonal immunoglobulin levels and had an acceptable tolerability profile with few treatment-related adverse events in these patients. This presentation and one discussing preclinical use of Interleukin 21 (IL-21) with Rituxan® were given at the American Society of Hematology annual meeting.